Noetic Fund

Numinus is a Vancouver-based company founded in 2019 by Payton Nyquvest and Stacey Wallin, specializing in psychedelic-centered therapeutic products and services. It integrates holistic healthcare approaches with neuro-technology to enhance patient care. Numinus operates a network of clinics, including Numinus Health, Mindspace Services, and the Neurology Center of Toronto, offering a range of services such as ketamine-assisted psychotherapy for conditions like depression, as well as neurological care and counseling by registered psychologists. The company is structured into several operational segments, including clinical research, its Canadian and US clinic networks, and corporate functions, with the majority of its revenue generated from the US segment. Through its laboratory and research and development initiatives, Numinus aims to advance the field of psychedelic therapy and improve mental health outcomes.

Diamond Therapeutics is a Toronto-based psychedelic drug development company dedicated to creating innovative therapies for mental health conditions. The company aims to harness the potential of psychedelic compounds, specifically focusing on sub-perceptual, non-hallucinogenic treatments that can be safely administered at home. By prioritizing these types of therapies, Diamond seeks to address the needs of a diverse patient population and enhance the efficacy of mental health treatments. The company’s approach includes psychopharmacology and biotechnology, with an emphasis on developing psilocybin-based medicines that may offer improved outcomes compared to existing first-line treatments, ultimately contributing to a positive impact on the global mental health crisis.

Damona Pharmaceuticals is a pre-clinical pharmaceutical company focused on treating and preventing cognitive deficits associated with various brain disorders and aging. The company develops small molecule therapeutics aimed at transforming the treatment of cognitive symptoms and restoring normal life functions for underserved and understudied mental health and aging populations. Their goal is to enable patients to potentially reverse impairments and resolve previously unresolvable symptoms.

Vessel Health, Inc. is a San Diego-based company founded in 2017 that specializes in at-home wellness tracking services. The company has developed a user-friendly application that allows individuals to test ten different health metrics in under ten minutes for a nominal fee. Utilizing biotechnology and the Internet of Things, the application instantly measures factors such as nutrient levels, hydration, cortisol, and toxins. Based on these results, Vessel Health provides tailored recommendations for diet, supplements, and lifestyle changes. The platform collaborates with experts, including doctors and nutritionists, to ensure that users receive accurate and effective wellness guidance. By offering various membership plans, Vessel Health enables users to monitor their health over time, helping them achieve better well-being and performance from the comfort of their homes.

Apollo Neuroscience, Inc. is a Pittsburgh-based company that manufactures a clinically validated wearable wellness device designed to assist the body in recovering from chronic stress through gentle vibrations. Established in 2016, the company also offers an application that integrates neuroscience and machine learning to enhance heart rate variability, promoting improved routines for waking, focusing, unwinding, and engaging the parasympathetic nervous system. The product is marketed directly to consumers through online sales and is positioned as a wellness solution rather than a treatment for psychiatric disorders.

Psygen is a manufacturer of pharmaceutical-grade psychedelic drug products specifically designed for clinical research and therapeutic applications. The company focuses on producing high-quality psychedelic substances to support healthcare researchers in accelerating the development of innovative treatments. By ensuring that these transformative products are understood and accessible, Psygen plays a crucial role in advancing the research landscape of psychedelic drugs, contributing to the potential benefits they may offer in various therapeutic settings.

Terran Biosciences Inc. is a biotechnology company focused on developing innovative solutions for neurological and mental health disorders. Established in 2017 and headquartered in New York, the company offers a diverse range of products, including a therapeutics pipeline, a medical device program, and a precision medicine platform. Terran Biosciences aims to create impactful therapies and technologies that can significantly improve the quality of life for patients suffering from neurological and psychiatric conditions.

Tactogen is a biopharma startup based in Palo Alto, California, founded in 2020 by neuroscientist Matthew Baggott and entrepreneur Luke Pustejovsky. The company specializes in the development of empathogen medicines aimed at promoting mental wellness and enhancing emotional connectivity. Through innovative drug discovery methods and the creation of novel pharmaceutical compounds, Tactogen focuses on producing safer and more effective empathogens that can be prescribed for at-home use. These medicines are designed to foster unique emotional states, balancing openness and motivation to support psychotherapeutic practices and improve decision-making processes. Tactogen's mission is to make these therapeutic options more accessible, contributing to advancements in psychology and mental health care.

Wake Network, Inc. is a Toronto-based company that specializes in clinical research and the development of wellness solutions through fungi and plant-based medicine. Founded in June 2018, it combines expertise from wellness professionals and advanced technology to create innovative healing benefits for the mind and body. The company has established a regenerative feedback loop, enabling it to conduct research, monitor outcomes, and integrate findings from clinical studies on a personalized basis. This approach positions Wake Network at the forefront of advancements in mental and holistic health.

CaaMTech, Inc. is a drug discovery and optimization company based in Issaquah, Washington, specializing in the engineering of psychedelic drugs. Founded in 2019, CaaMTech focuses on creating and refining psychedelic compounds and formulations through rigorous scientific methods and innovative approaches. The company aims to enhance health and well-being by developing psychedelic medicines intended to address various conditions, including depression and PTSD. In addition to its drug development efforts, CaaMTech also offers drug safety and efficacy screening services, contributing to the advancement of psychedelic therapies in the health industry.

Sana Health, Inc. is a digital health company based in Lafayette, Colorado, with an additional office in Mill Valley, California. Founded in 2015, the company specializes in developing bio-therapeutic devices designed to promote relaxation and alleviate pain and tension. Its flagship product, Sana, is a non-addictive mask and headphone combination that utilizes audiovisual stimulation to enhance the balance between the left and right sides of the brain, facilitating a deep meditative state. This device employs coordinated pulses of light and sound to guide users into relaxation, mimicking the benefits of long-term meditation practices. Sana Health is also engaged in multiple clinical studies, focusing on applications for conditions such as fibromyalgia and neuropathic pain, as well as trials related to anxiety and PTSD. The company offers its products for sale online and provides a mobile application accessible via major app platforms.

Merlyn Mind is a technology company founded in 2018 and based in New York, focused on delivering AI-driven solutions to the education sector. Its flagship product, Merlyn, is an AI-powered digital assistant designed to enhance the teaching and learning experience. This assistant integrates custom hardware and software to understand natural voice commands and remote control inputs from educators, enabling them to manage multimedia applications effortlessly during lessons. By optimizing wake-word architecture and remote control functionality, Merlyn empowers teachers to leverage technology more intuitively in their classrooms, ultimately facilitating a more interactive and engaging learning environment.

Apollo Neuroscience, Inc. is a Pittsburgh-based company that manufactures a clinically validated wearable wellness device designed to assist the body in recovering from chronic stress through gentle vibrations. Established in 2016, the company also offers an application that integrates neuroscience and machine learning to enhance heart rate variability, promoting improved routines for waking, focusing, unwinding, and engaging the parasympathetic nervous system. The product is marketed directly to consumers through online sales and is positioned as a wellness solution rather than a treatment for psychiatric disorders.

Woven Science is a life sciences platform focused on creating a comprehensive solution for mental healthcare, particularly through psychedelic therapeutics. The company aims to establish one of the first vertically integrated patient care systems in this field, encompassing all stages from drug development to clinic distribution. Woven Science emphasizes a model of mutuality, balancing purpose and profit, and is notable for its commitment to social responsibility by allocating 10% of its realized profits to nonprofits dedicated to supporting indigenous culture and ecosystem preservation. By building, backing, and incubating innovative companies within its ecosystem, Woven Science seeks to address the mental illness epidemic with a focus on delivering scalable and effective mental health outcomes throughout the treatment process.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York, focused on developing innovative psychotropic drugs to address mental health issues. Founded in 2019, the company specializes in creating novel compounds that enhance the benefits of traditional psychedelics, improving parameters such as safety, tolerability, duration, and efficacy. Gilgamesh targets a range of neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. With the growing global mental health crisis, the company aims to accelerate the development of new treatments that meet the urgent need for effective solutions in mental health care, leveraging its expertise in medicinal chemistry and drug development.

Bexson Biomedical is focused on developing an innovative subcutaneous delivery system for ketamine, aimed at treating chronic and acute pain disorders. The company’s lead product features a unique formulation of ketamine, which is administered through a minimally invasive, wearable infusion pump. This system addresses the limitations of existing ketamine preparations by helping to control overdosing risks and reducing the need for continuous monitoring. By enhancing the delivery method, Bexson Biomedical seeks to provide physicians with an effective tool for pain management.

People Science is a technology-driven research and development platform focused on alternative medicine. The company facilitates connections between health-conscious individuals, medical professionals, and research scientists, fostering collaboration in the exploration of alternative therapeutic options. By assisting manufacturers in developing scientifically validated products, People Science aims to enhance consumer understanding of alternative medicines and their potential benefits for health and wellness. Through its innovative approach to clinical research, the company seeks to provide a comprehensive framework that supports the advancement of alternative medicine, ensuring that products are backed by rigorous scientific testing and research.

Frequency Breathwork is a fitness platform that offers live-streamed virtual breathwork classes, training sessions, and events. Its primary goal is to enhance emotional well-being by helping users reduce anxiety and depression, improve sleep quality, boost energy levels and mental clarity, optimize bodily functions, and induce states of heightened consciousness. The platform aims to provide clients with access to a calm and connected state of being, enabling them to tune into their home frequency and unlock their full potential.

Beckley Psytech Limited is a biotechnology company based in Oxford, United Kingdom, that develops psychedelic drugs aimed at treating psychiatric and neurological disorders. Founded in 2014, it focuses on harnessing the therapeutic potential of substances such as psilocybin to address significant mental health challenges, including depression and other debilitating neuropsychiatric conditions with considerable unmet needs. The company aims to integrate clinically validated psychedelic medicines into mainstream medical practices, offering patients innovative treatment options that differentiate from existing therapies. Through its drug pipeline, Beckley Psytech is committed to providing alternative solutions for those suffering from various mental health issues.

The Alexander Shulgin Research Institute (ASRI) is dedicated to the discovery and development of psychedelic substances, focusing on their potential therapeutic applications. The organization operates as a research platform for medicinal drugs, specifically aimed at identifying new compounds that induce psychedelic experiences in healthy individuals. ASRI engages in the chemical synthesis and pharmacological evaluation of these novel substances, striving to enhance the healthcare industry’s understanding and utilization of psychedelics. Additionally, the institute emphasizes education related to psychedelic research, contributing to a broader discourse on their medicinal benefits and applications.

Eleusis is a clinical stage life science company focused on harnessing the therapeutic potential of serotonin 2A receptor agonists, commonly known as psychedelics. The company aims to develop innovative psychedelic drug therapies that address unmet medical needs, particularly in the field of psychiatry and beyond. Eleusis is advancing a novel approach to transform psilocybin into a safe, effective, convenient, and affordable treatment option for depression. By doing so, the company seeks to provide healthcare providers and pharmaceutical companies with viable alternatives to conventional therapies, thereby broadening the scope of treatment options available to patients.

Cybin is a biopharmaceutical company dedicated to advancing research and development in psychedelic and medicinal mushrooms. It focuses on creating safe and effective therapeutics for mental health issues, with an emphasis on psilocybin-based products. The company is actively launching these products in jurisdictions where they are permitted and is engaged in clinical studies across North America and other regions. Through strategic partnerships with academic and institutional entities, Cybin seeks to develop novel compounds and delivery mechanisms, aiming to provide innovative treatments for various psychiatric and neurological conditions.

COMPASS Pathways is a mental health care company based in Cheshire, United Kingdom, with operations in the United States. The company is focused on developing innovative therapies for treatment-resistant depression (TRD) using its proprietary psilocybin formulation, COMP360. Currently undergoing Phase IIb clinical trials, COMP360 aims to provide a new treatment option for patients who have not responded to traditional depression therapies. COMPASS Pathways emphasizes the combination of psilocybin-assisted therapy with psychological support to enhance treatment efficacy. The company is committed to addressing the significant unmet needs in mental health care by advancing evidence-based solutions for those suffering from mental health challenges.

Eve Health Systems is a data-driven health platform that helps patients to connect with their clinicians.